Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150982 · ClinicalTrials.gov registry record · Phase 2
Alefacept Mechanism of Action in Psoriasis
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00150982: Completed Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00150982 is a Phase 2 study that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00150982, a Phase 2 study, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To determine the mechanism of action of alefacept in patients with psoriasis.
Interventions
- DRUG Mechanism of action of alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00150982 record still lists
NCT00150982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Mechanism of action of alefacept is the first listed.
NCT00150982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00150982 about?
NCT00150982 is a clinical study titled "Alefacept Mechanism of Action in Psoriasis". To determine the mechanism of action of alefacept in patients with psoriasis.
What is the current status of trial NCT00150982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2003-09. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00150982?
The interventions under investigation include: Mechanism of action of alefacept (DRUG).
Who is sponsoring clinical trial NCT00150982?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00150982's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia